Clinical Scorecard: Isarna Reports Antisense Therapy Trial Data
At a Glance
| Category | Detail |
|---|---|
| Condition | Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) |
| Key Mechanisms | Targeting transforming growth factor beta-2 (TGF-β2) to reduce fibrosis and improve vision |
| Target Population | Patients with nAMD and DME |
| Care Setting | Clinical trial setting in Austria and India |
Key Highlights
- Phase 2 BETTER trial showed stable or improved vision with ISTH0036 injections every 8 weeks
- Reduction in central retinal thickness and fibrotic tissue volume in nAMD patients
- ISTH0036 reduced intraretinal fluid in DME patients, both treatment-naïve and previously treated
- No elevation in intraocular pressure reported, indicating good tolerability
- Current therapies do not directly target TGF-β2 pathway
Guideline-Based Recommendations
Diagnosis
- Assess visual acuity and central retinal thickness in patients with nAMD and DME
Management
- Consider ISTH0036 for patients with nAMD and DME in clinical trial settings
Monitoring & Follow-up
- Monitor vision changes and retinal thickness during treatment
Risks
- No significant risks reported; well tolerated with no intraocular pressure elevation
Patient & Prescribing Data
Patients with neovascular age-related macular degeneration and diabetic macular edema
ISTH0036 shows promise in improving vision and reducing retinal fluid without significant side effects
Clinical Best Practices
- Evaluate patients for eligibility in clinical trials for novel therapies like ISTH0036
- Regularly monitor retinal health and visual acuity in patients receiving treatment
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.